Publisert 25.06.2019

Board Meeting No 5 2019

Board Meeting No 5. June 25th 2019

Regenics AS have developed clinical proof of efficacy and safety  in human 2 degree burn wounds for our products Collex® and Vernex®.

The procudts are beeing developed as class III devices. WoundClear® is developed as a BLA/EU CP biotech drug.